2022
The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: A secondary analysis of pooled data
Wang M, Bandla A, Sundar R, Molassiotis A. The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: A secondary analysis of pooled data. European Journal Of Oncology Nursing 2022, 60: 102196. PMID: 36067640, DOI: 10.1016/j.ejon.2022.102196.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyMeasuring chemotherapy-induced peripheral neuropathyNerve conduction studiesQuality of lifePeripheral neuropathySecondary analysisSecondary analysis of pooled dataPerformance of nerve conduction studiesNerve conduction study resultsNerve conduction study parametersTime points of assessmentInitiation of chemotherapyPatient-reported symptomsOxaliplatin-based chemotherapyPooled dataClinical examination outcomeAnalysis of pooled dataConduction studiesCIPN assessmentMonitoring peripheral neuropathyNeurotoxic chemotherapyProspective studyClinical examinationSensory nervesChemotherapy
2017
Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients.
Walsh R, Lee S, Seng K, Wang L, Ho G, Ow S, Kumarakulasinghe N, Sundar R, Lee X, Yap H, Jeyasekharan A, Pang A, Ho J, Tan C, Lim Y, Malik R, Wan Ishak W, Goh B, Tai B, Wong A. Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. Journal Of Clinical Oncology 2017, 35: 1056-1056. DOI: 10.1200/jco.2017.35.15_suppl.1056.Peer-Reviewed Original ResearchClinical benefit rateMetastatic breast cancerHormone receptorsMetastatic breast cancer patientsUDP-glucuronosyltransferaseClinical treatment efficacyGlucuronidation in vitroUGT2B17 genotypeBenefit rateClinical benefitProspective studyBreast cancerActive metabolitePK dataPD biomarkersTreatment efficacyPatientsPharmacodynamicsPD effectsResponse rateUGT2B17C maxActivity indexPharmacokineticsSignificant PD